PLRX Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own PLRX shares is 233, representing 111.88% of the company's common stock.

ENSIGN PEAK ADVISORS, INC, in the last quarter, reduced its stake in PLRX by -4.8% restricting it's holding to 25.42 thousand shares of worth nearly $378.73K. BLACKROCK INC. also lessened -3.04% of the PLRX shares from its portfolio, reducing its holding to 4.66 million shares of worth $69.37M. FMR LLC also shunned PLRX shares holding by -0.43% last quarter which brought its holding to 3.95 million shares worth $58.80M.

As per its latest 13F filing, VANGUARD GROUP INC increased its stake in PLRX by 13.45% in the last quarter. The institutional holder raised its holding to 3.48 million shares having worth more than $51.83M. GREAT POINT PARTNERS LLC also added 1.57% more shares of PLRX to its portfolio, raising its holding to 1.85 million shares of worth $27.59M. CITADEL ADVISORS LLC also increased its PLRX shares holding by 7.81% which brought its holding to 1.7 million shares worth $25.36M.

The insider with the most stakes in PLRX is Coulie Bernard , President and CEO at the company. Additionally, PLRX stock is highly held by Chief Financial Officer Cummings Keith Lamont and Chief Business Officer Hull Hans among others.

Company executives, directors, and other insiders own 2.91% percent of Pliant Therapeutics, Inc.'s stock. Within the last six months, there have been 7 transaction(s) in which PLRX insiders have sold stock, totaling 134.22K shares. Insiders that have sold shares include OUIMETTE MIKE, CUMMINGS KEITH LAMONT, and COULIE BERNARD.

There have been 0 transaction(s) during the past 6-months in which Pliant Therapeutics, Inc. insiders have bought stock, totalling 0 shares

Around 1.28M Pliant Therapeutics, Inc. shares are held by insiders, which represents about 2.91% of PLRX stock.

PLRX President and CEO, Coulie Bernard holds the largest portfolio of the company's shares. PLRX shares owned by Coulie total nearly 430.52 thousand.

TD ASSET MANAGEMENT INC is the largest institutional owner in PLRX which holds 112.25 thousand shares worth $1.67M or 0.19% of the total PLRX shares outstanding followed by ENSIGN PEAK ADVISORS, INC with ownership of 25.42 thousand shares representing 0.04% of the PLRX ownership. BLACKROCK INC. is the third largest stakeholder with 4.66 million shares or 7.93% of the ownership worth more than $69.37M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the PLRX is concerned, it is a stock which is optionable.

Number of PLRX shares short is 7.17M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 60.85M shares of PLRX are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, PLRX has 46.87M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for PLRX is 11.92.